Financial presentations
Financial presentations
Redeye interview with Anders Hultman CEO. Commenting on the Interim Report Q2 2025
Anders Hultman, CEO, presenting.
Redeye Theme Event: Medtech
2025-05-08
Anders Hultman, CEO, presenting.
Redeye Technology & Life Science Day 2024
2024-12-03
Anders Hultman, CEO, presenting.
Redeye Fight Cancer Event 2024
2024-01-24
Anders Hultman, CEO, & Scientific Advisor Prof. Stig Linder presenting.
AroCell Business Update
November 28 2023
Introduction – Anders Hultman, CEO
Financial Position – Ellen Dittberner, CFO
Laboratory Tests – Marie Torstensson, CMO
Rapid Tests – Gunnar Wahlberg, CSO
Clinical Program and Development – Kiran Jagarlamudi, CScO, and Prof. Stig Linder, Scientific Advisor.
Q&A with Redeye Equity Analyst – Oscar Bergman
Watch it here: Link
Redeye interview with Anders Hultman CEO. Commenting on the Interim Report Q3 2023
2023-11-06
CEO Anders Hultman presents at Redeye Medtech & Diagnostics Event
2023-09-26
Redeye interview with Anders Hultman CEO. Commenting on the Interim Report Q2 2023
2023-08-25
Redeye interview with Anders Hultman CEO. Commenting on the Year-end report Q4Â 2022
2023-02-27
Strategy Update Day 2022
2022-11-22
Redeye interview with Anders Hultman CEO. Commenting on the Interim report Q3 2022
2022-10-28
Anders Hultman CEO presents at Redeye Diagnostics Seminar 2022
2022-09-27
Redeye interview with Anders Hultman CEO. Commenting on the Interim report Q2 2022
2022-08-17
Redeye interview with Anders Hultman CEO. Commenting on the Interim report Q1 2022
2022-05-03
Redeye interview with Anders Hultman CEO. Commenting on the Interim report Q4 2021
2022-03-02
Redeye transactions, presenting Anders Hultman CEO.
2022-02-03
Redeye interview with AroCell CEO, Anders Hultman. Commenting on the Interim report Q3 2021
2021-11-16
AroCell’s CEO, Anders Hultman, commenting the company’s updated strategy following the merger with IDL Biotech.
2021-10-06
Redeye interview with AroCells CEO, Anders Hultman. Commenting on the Interim report Q2 2021
2021-09-02
Interview with Anders Hulman and Peter Löwendahl.
2021-08-12 (In Swedish)
Growth day 2021 – AroCells CEO Anders Hultman.
Redeye intervju with AroCells CEO Anders Hultman.
2021-05-19
Redeye intervju with AroCells CEO Anders Hultman.
2021-05-10
Investor forum online, Anders Hultman, CEO, presenting.
2021-03-04
Redeye interview with AroCell CEO, Anders Hultman. Commenting on the Interim report Q4 2020
2021-02-19
Anders Hultman, CEO, commenting on FDA delay due to covid-19.
2021-01-20
Commenting AroCells CEO transition.
2021-01-12
Life science day 2020
Redeye Theme Event: Medtech
2025-05-08
Anders Hultman, CEO, presenting.
Redeye Technology & Life Science Day 2024
2024-12-03
Anders Hultman, CEO, presenting.
Redeye Fight Cancer Event 2024
2024-01-24
Anders Hultman, CEO, & Scientific Advisor Prof. Stig Linder presenting.
AroCell Business Update
November 28 2023
Introduction – Anders Hultman, CEO
Financial Position – Ellen Dittberner, CFO
Laboratory Tests – Marie Torstensson, CMO
Rapid Tests – Gunnar Wahlberg, CSO
Clinical Program and Development – Kiran Jagarlamudi, CScO, and Prof. Stig Linder, Scientific Advisor.
Q&A with Redeye Equity Analyst – Oscar Bergman
Watch it here: Link
Redeye interview with Anders Hultman CEO. Commenting on the Interim Report Q3 2023
2023-11-06
CEO Anders Hultman presents at Redeye Medtech & Diagnostics Event
2023-09-26
Redeye interview with Anders Hultman CEO. Commenting on the Interim Report Q2 2023
2023-08-25
Redeye interview with Anders Hultman CEO. Commenting on the Year-end report Q4Â 2022
2023-02-27
Strategy Update Day 2022
2022-11-22
Redeye interview with Anders Hultman CEO. Commenting on the Interim report Q3 2022
2022-10-28
Anders Hultman CEO presents at Redeye Diagnostics Seminar 2022
2022-09-27
Redeye interview with Anders Hultman CEO. Commenting on the Interim report Q2 2022
2022-08-17
Redeye interview with Anders Hultman CEO. Commenting on the Interim report Q1 2022
2022-05-03
Redeye interview with Anders Hultman CEO. Commenting on the Interim report Q4 2021
2022-03-02
Redeye transactions, presenting Anders Hultman CEO.
2022-02-03
Redeye interview with AroCell CEO, Anders Hultman. Commenting on the Interim report Q3 2021
2021-11-16
AroCell’s CEO, Anders Hultman, commenting the company’s updated strategy following the merger with IDL Biotech.
2021-10-06
Redeye interview with AroCells CEO, Anders Hultman. Commenting on the Interim report Q2 2021
2021-09-02
Interview with Anders Hulman and Peter Löwendahl.
2021-08-12 (In Swedish)
Growth day 2021 – AroCells CEO Anders Hultman.
Redeye intervju with AroCells CEO Anders Hultman.
2021-05-19
Redeye intervju with AroCells CEO Anders Hultman.
2021-05-10
Investor forum online, Anders Hultman, CEO, presenting.
2021-03-04
Redeye interview with AroCell CEO, Anders Hultman. Commenting on the Interim report Q4 2020
2021-02-19
Anders Hultman, CEO, commenting on FDA delay due to covid-19.
2021-01-20
Commenting AroCells CEO transition.
2021-01-12
Life science day 2020
About us
We provide knowledge to decision.
IDL Diagnosticsis a Swedish diagnostics company with the vision to improve the monitoring of oncological and bacterial diseases. We have a broad product portfolio of IVD tests that deliver high-value clinical information for the detection of diseases.
Bacteriology
An effective typhoid test
Typhoid fever is water and food-borne infectious disease caused by the bacterium, Salmonella enterica. IDL Biotechs product TUBEX® TF, is a rapid and sensitive in vitro diagnostic test for the detection of acute typhoid fever.
Oncology
Diagnostics for oncology
Cancer is one of the leading causes of death worldwide, despite advancing knowledge. To improve cancer patient management, there is a clear need for efficient diagnostics tools to capture this critical clinical data.
